Patients with severe heart failure supported by left ventricular assist device (LVAD) require
adequate long-term anticoagulant therapy. New oral anticoagulants such as the direct thrombin
inhibitor dabigatran may represent an alternative to Coumarin for long-term anticoagulation.
In this pilot single-center study, thirty LVAD patients with stable renal function were
scheduled to receive phenprocoumon or dabigatran for long-term anticoagulation after
implantation of a HeartWare HVAD system following an open-label balanced parallel group